AI Article Synopsis

  • Diabetes is a complex disorder that requires treatments with multiple effective agents for better management.
  • The study describes the creation of polyhydroxylated pyrrolidines that can inhibit two important enzymes, alpha-glucosidase and aldose reductase, which are linked to increased blood sugar levels and tissue damage in diabetes.
  • One specific compound, 17b, not only reduced cell death but also helped restore normal oxidative stress levels in lab tests, indicating its potential effectiveness in treating diabetic retinopathy.

Article Abstract

Diabetes is a multi-factorial disorder that should be treated with multi-effective compounds. Here we describe the access to polyhydroxylated pyrrolidines, belonging to the d-gluco and d-galacto series, through aminocyclization reactions of two differentially protected d-xylo-hexos-4-ulose derivatives. The prepared compounds proved to inhibit both alpha-glucosidase, responsible for the emergence of hyperglycemic spikes, and aldose reductase, accountable for the development of abnormalities in diabetic tissues. Accordingly, they show the dual inhibitory profile deemed as ideal for diabetes treatment. Significantly, compound 17b reduced the process of cell death and restored the physiological levels of oxidative stress when tested in the photoreceptor-like 661w cell line, thus proving to be effective in an in vitro model of diabetic retinopathy.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bioorg.2019.103298DOI Listing

Publication Analysis

Top Keywords

aldose reductase
8
synthesis investigation
4
investigation polyhydroxylated
4
polyhydroxylated pyrrolidine
4
pyrrolidine derivatives
4
derivatives novel
4
novel chemotypes
4
chemotypes showing
4
showing dual
4
dual activity
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!